Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial

• Published in: Clinical cancer research Vol. 23; no. 12; pp. 2961 - 2971
• Main Authors: Lowenfeld, Lea, Mick, Rosemarie, Datta, Jashodeep, Xu, Shuwen, Fitzpatrick, Elizabeth, Fisher, Carla S., Fox, Kevin R., DeMichele, Angela, Zhang, Paul J., Weinstein, Susan P., Roses, Robert E., Czerniecki, Brian J.
• Format: Journal Article
• Language: English
• Published: Philadelphia American Association for Cancer Research Inc 15.06.2017
• Subjects: Anticancer properties; Antitumor activity; Blood; Breast cancer; Cancer; CD4 antigen; Dendritic cells; Enzyme-linked immunosorbent assay; ErbB-2 protein; Experimental design; Immune response; Immune system; Immunogenicity; Injection; Invasiveness; Lymph nodes; Lymphatic system; Lymphocytes T; Patients; Peripheral blood; Surgery; T cell receptors; Vaccination

Abstract Purpose: Vaccination with HER2 peptide-pulsed DC1s stimulates a HER2-specific T-cell response. This randomized trial aimed to establish safety and evaluate immune and clinical responses to vaccination via intralesional (IL), intranodal (IN), or both intralesional and intranodal (ILN) inject...